New genetic screening techniques to test embryos before implantation are making their way into fertility centers.
Menlo Park, California-based MyOme and New Jersey-based Genomic Prediction now use the genetic sequences of parents along with cells retrieved during a biopsy to generate an embryo’s entire genome. Next, they use algorithms to calculate the probabilities of certain ailments. Couples can then select the embryos they like, based on those results.
While both companies are disease focused for now, it is also possible to calculate scores and optimize for other genetic traits like height and intelligence.
Accountants, Advertising/Public Relations/Marketing, Aerospace, Auditors, Biosciences, Builders/General Contractors, Casinos/Gambling, Chemical & Related Manufacturing, Civil Servants/Public Officials, Clergy & Religious Organizations, Clothing Manufacturing, Construction, Covid-19/ coronavirus, Defense, Doctors & Other Health Professionals, Drug Manufacturers, Education Colleges & Universities, Entertainment Industry, Environment, Fitness Companies, Government Regulators, Health Professionals, Hospitality, Information Technology, Infrastructure, Insurance, Law Enforcement, Lawyers/Law Firms/Legal Industry, Lobbyists, Luxury Retail, Manufacturing, National Security, Pharmaceuticals/Health Products, Professional Sports, Retail, Technology Company, Trade Associations, Waste Management